Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Finished Goods (2016 - 2018)

Historic Finished Goods for Amicus Therapeutics (FOLD) over the last 3 years, with Q1 2018 value amounting to $865000.0.

  • Amicus Therapeutics' Finished Goods rose 28444.44% to $865000.0 in Q1 2018 from the same period last year, while for Mar 2018 it was $865000.0, marking a year-over-year increase of 28444.44%. This contributed to the annual value of $780000.0 for FY2017, which is 62222.22% up from last year.
  • As of Q1 2018, Amicus Therapeutics' Finished Goods stood at $865000.0, which was up 28444.44% from $780000.0 recorded in Q4 2017.
  • Amicus Therapeutics' Finished Goods' 5-year high stood at $865000.0 during Q1 2018, with a 5-year trough of $57000.0 in Q2 2016.
  • Its 3-year average for Finished Goods is $337500.0, with a median of $207500.0 in 2017.
  • The largest annual percentage gain for Amicus Therapeutics' Finished Goods in the last 5 years was 62222.22% (2017), contrasted with its biggest fall of 13928.57% (2017).
  • Quarter analysis of 3 years shows Amicus Therapeutics' Finished Goods stood at $108000.0 in 2016, then surged by 622.22% to $780000.0 in 2017, then increased by 10.9% to $865000.0 in 2018.
  • Its last three reported values are $865000.0 in Q1 2018, $780000.0 for Q4 2017, and $335000.0 during Q3 2017.